Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Oct;99(4):361-369.
doi: 10.1111/cen.14956. Epub 2023 Aug 1.

Efficacy of a basal insulin dose management smartphone application for controlling fasting blood glucose in patients with type-2 diabetes mellitus: A single-centre, randomised clinical study

Ensi Luo  1 , Jiejun Wan  1 , Minting Su  2 , Jieying Wang  2 , Jiahua Feng  3 , Xia Xie  4 , Xiaocheng Hong  5
Affiliations
Randomized Controlled Trial

Efficacy of a basal insulin dose management smartphone application for controlling fasting blood glucose in patients with type-2 diabetes mellitus: A single-centre, randomised clinical study

Ensi Luo et al. Clin Endocrinol (Oxf). 2023 Oct.

Abstract

Objective: To explore the efficacy and safety of the 'Walk with you' application for titrating basal insulin (BI) doses in type-2 diabetes mellitus (T2DM) hospitalised patients.

Methods: This was a randomised, single-centre, open-label, controlled clinical trial to compare the changes in fasting blood glucose (FBG) and postprandial blood glucose (PBG), time to reach target FBG (FBG-TRT), incidence of hypoglycaemia events and FBG coefficient of variation in the application group (weight-based titration of BI dose regimen) and control group (typical adjustment regimen).

Patients: This study selected 173 patients with T2DM using basal-prandial insulin therapy who were admitted to Binhaiwan Central Hospital of Dongguan between December 2021 and December 2022. Patients were randomised to the control group or the application group (App group) and then titrated to achieve an FBG concentration of less than 7.0 mmol/L.

Results: There were 86 patients in the control group and 87 patients in the App group. The FBG concentrations in the control and App groups were decreased by 6.77 ± 4.75 and 5.95 ± 4.06 mmol/L, respectively. The FBG-TRTs in the control and App groups were 3.80 ± 1.52 and 2.82 ± 1.34 days, respectively (p < .001). Fewer patients in the control group reached the FBG-TRT within 3 days than in the App group, with 46.5% and 71.3% of patients reaching that target, respectively. There was no significant between-group difference in hypoglycaemia incidence.

Conclusion: The use of this weight-based insulin dose titration protocol for BI app is effective and safe for achieving the target FBG in noncritically ill patients with T2DM and is free, easy to use and user friendly.

Keywords: application; basal insulin; dose titration; fast blood glucose; type-2 diabetes mellitus.

PubMed Disclaimer

Similar articles

See all similar articles

References

REFERENCES

    1. Jia W, Weng J, Zhu D, et al. Standards of medical care for type 2 diabetes in China 2019. Diabetes Metab Res Rev. 2019;35(6):e3158.
    1. American Diabetes Association Professional Practice Committee. 16. Diabetes care in the hospital: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(suppl 1):S244-S253.
    1. Christensen MB, Gotfredsen A, Nørgaard K. Efficacy of basal-bolus insulin regimens in the inpatient management of non-critically ill patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2017;33(5):e2885.
    1. Hu C, Jia W. Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication. Diabetes. 2018;67(1):3-11.
    1. Kuritzky L, Reid TS, Wysham CH. Practical guidance on effective basal insulin titration for primary care providers. Clin Diabetes. 2019;37(4):368-376.

Publication types

LinkOut - more resources